Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Aushon BioSystems Appoints Industry Veteran Susan Vogt Chief Executive Officer

Published: Tuesday, April 16, 2013
Last Updated: Tuesday, April 16, 2013
Bookmark and Share
Former SeraCare CEO and Millipore executive to guide strategic direction of life sciences services and technology company.

Aushon BioSystems announced the appointment of Susan Vogt as chief executive officer. Vogt brings more than 30 years of experience in the global life science research, pharmaceutical, biotech and clinical diagnostics markets to her new role. Founder and former CEO Pete Honkanen will assume the role of chief operating officer and continue as a board director.

Vogt's experience includes leadership roles at both small and large private and public companies. Most recently, Vogt led the turnaround of diagnostics reagents company SeraCare Life Sciences as president and CEO, where she successfully re-listed the company on NASDAQ and returned the company to growth and profitability. Previously, Vogt held numerous senior level positions at Millipore Corporation, including corporate officer and president of the company’s biopharmaceutical division. She currently serves as non-executive director of TAP BioSystems, and has previously served on the board of directors and advisory boards of a number of other private and publicly-held companies. Vogt holds an MBA from Boston University and a BA from Brown University.

“With sound technology, an elegant, easy-to-use platform and a strong customer base, Aushon is well-positioned to lead the market as the demand for multiplexing in the life sciences continues to grow,” said Vogt. “Our technology enables research that’s critical to the development of both therapeutics and diagnostics, and I look forward to driving the company’s future growth.”

Aushon provides a suite of multiplex immunoassay products and services for the discovery and development of the biomarkers necessary to enable personalized medicine innovation. Multiplexing involves simultaneously measuring and comparing multiple proteins – an improvement over today’s standard which measures one at a time. Fueled by a growing market for multiplexing, Aushon recently announced an anticipated 30 percent year-over-year revenue growth in 2013 and added Thomas Mac Mahon, former president and CEO of Laboratory Corporation of America® Holdings (LabCorp®), to its board of directors.

“Susan is joining Aushon at an exciting time, as we’re expanding to meet increasing demand for our technologies and services by pharmaceutical, biotech and other life sciences research organizations,” said Honkanen. “Her appointment is further evidence of Aushon’s momentum in helping our customers drive the development of new tests and therapies, enabling personalized medicine and, ultimately, better healthcare for patients.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Aushon BioSystems and Peking University Cancer Hospital to Collaborate
Aushon BioSystems, Inc. announced that it has signed a letter of intent to enter into a diagnostic development collaboration with Peking University Cancer Hospital (“PUCH”), Beijing, China. The primary goal for the collaboration is to develop predictive diagnostic markers for liver metastases of colorectal cancer.
Friday, February 11, 2011
Scientific News
Breast Cancer Cells Found To Switch Molecular Characteristics
Spontaneous interconversion between HER2-positive and HER2-negative states could contribute to progression, treatment resistance in breast cancer.
Some Breast Cancer Patients With Low Genetic Risk Could Skip Chemotherapy
Genetic test can help predict survival and guide treatment options.
Lose Weight, Escape the Eight: Weight-Based Cancer Risk
IARC has identified eight additional cancer sites linked to overweight and obesity.
Coffee Consumption Linked to Genes
Researchers have identified a gene that influences coffee consumption. The gene is thought to relate to caffeine breakdown.
Emerging Model of Cancer
Cancer acts cooperatively, making individual decisions but acting in unison; this insight is being used to create a computer model of cancer.
Biological Barcodes Using CRISPR
Using genome editing tools, researchers are getting closer to understand differentiation of various cell types during development.
Controlling DNA Repair
Scientists discover that DNA repair outcomes following CRISPR-Cas9 cleaving are non-random and can be harnessed to produce desired effects.
Demonstrating LNP Delivery of CRISPR Components
Intellia has presented data demonstrating in vivo gene editing ising liquid nanoparticles (LNPs) to deliver CRISPR/Cas9.
Gene Therapy Via Ultrasound
Research into a gene therapy approach called sonoporation could help combat heart disease and cancer.
Creating Embryos with 'Heteroplasmy'
New discovery in genetic research could lead to treatments for mitochondrial diseases.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!